Listas Anotadas de Medicamentos e Dispositivos

Valproic acid (sodium valproate)

Injection 100 mg/mL in 4 mL ampoule Injection 100 mg/mL in 10 mL ampoule Oral liquid 200 mg/5 ml Oral liquid 250 mg/5 mL Oral Solution (drops) 10 mg/drop Solution 250 mg/5 mL Tablet 250 mg Tablet 260 mg Tablet 500 mg Tablet (crushable) 100 mg Tablet (enteric-coated) 200 mg (sodium valproate) Tablet (enteric-coated) 500 mg (sodium valproate)

Este medicamento esta presente em:

Listas	Seção	Observação
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	Sem observações
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.

Este medicamento esta presente em:

Listas	Seção	Observação
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	Sem observações
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	Sem observações
Bolivia	LINAME 2011 - 2013	Sem observações
Peru	05. Anticonvulsants/Antiepileptics	Sem observações
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb

Este medicamento esta presente em:

Listas	Seção	Observação
Chile	Essential and Prioritized Medications	Sem observações
Colombia	13.4 Anticonvulsants	Sem observações
Venezuela (incomplete)	List of Generic Medications - Venezuela	Sem observações
Cuba	05. ANTICONVULSIVOS	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
Chile	Essential and Prioritized Medications	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
Bolivia	LINAME 2011 - 2013	Sem observações
Peru	05. Anticonvulsants/Antiepileptics	Sem observações
Ecuador	Essential Medicines List - Ecuador	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
Colombia	13.4 Anticonvulsants	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
Venezuela (incomplete)	List of Generic Medications - Venezuela	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
Cuba	05. ANTICONVULSIVOS	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	Sem observações
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	Sem observações
WHO Model List of Essential Medicines (2021)	24.2.2. Medicines used in bipolar disorders	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
Chile	Essential and Prioritized Medications	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	05. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
PAHO Strategic Fund Medicine List	12. Anticonvulsant and antiepileptic	Sem observações
Bolivia	LINAME 2011 - 2013	Sem observações
WHO Model List of Essential Medicines (2021)	24.2.2. Medicines used in bipolar disorders	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
Peru	05. Anticonvulsants/Antiepileptics	Sem observações
Peru	24.2.2 For Bipolar Disorder	Sem observações
Ecuador	Essential Medicines List - Ecuador	Sem observações
Venezuela (incomplete)	List of Generic Medications - Venezuela	Sem observações
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb
Training CSamouge 2022	5. ANTICONVULSANTS/ ANTIEPILEPTICS	Outras observações: Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb

Recursos de Informação: Valproic acid (sodium valproate)

Nenhuma informação disponível